Pascal Sanchez, PhD
Download a Printable PDF
More about Dr. Sanchez
Dr. Pascal Sanchez's research focuses on finding ways to prevent or reverse the cognitive decline seen in patients suffering from neurodegenerative conditions such as Alzheimer’s disease. Specifically, he is interested in understanding why the complex network of brain cells, or neurons, becomes dysfunctional in Alzheimer’s. In 2012, he found that the FDA-approved epilepsy drug levetiracetam could reduce these dysfunctions in animal models of the disease, suggesting a novel therapeutic strategy to fight Alzheimer’s. He is actively pursuing this research to advance this discovery towards clinical trials. In addition, he is also leading drug-discovery projects through collaborations with industry partners such as Bristol-Myers Squibb and Takeda.
A native of France, Dr. Sanchez obtained a PhD in Physiology and Neuroscience from the Institute of Molecular and Cellular Physiology at the University of Lyon in 2008. He then joined Gladstone as a postdoctoral research scientist in the laboratory of Gladstone Senior Investigator Lennart Mucke, MD. In 2013 he became a Staff Research Scientist at Gladstone.
Dr. Sanchez has received numerous awards and fellowships, including the Outstanding Young Investigator Award from the Alzheimer’s Drug Discovery Foundation and a PhD fellowship from the French Minister of Defense. In 2010 he was awarded a grant by the Alzheimer’s Disease Research Center at the University of California, San Francisco, for work on a promising strategy to treat Alzheimer’s disease.